Biotech
AbCellera
AbCellera raises $555M Series B at $5.7B valuation
$555M
Total Raised
Series B
Latest Round
2012
Founded
400+
Employees
2389 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
1 min read
Quick Facts
Valuation
$5.7B
Latest Round Size
$555M
Latest Round Date
June 2024
AbCellera: Series B Funding Round
AbCellera has successfully raised $555M in Series B funding, reaching a valuation of $5.7B.
Company Overview
Antibody discovery platform
Funding Details
The Series B round was led by Peter Thiel, with participation from Eli Lilly, Fast Forward Innovations, DCVC Bio.
Company Information
- Headquarters: 2389 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
- Founded: 2012
- Employees: 400+
- Category: Biotech
Investment
AbCellera plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Peter Thiel: Verified investor in Series B
- Eli Lilly: Verified investor in Series B
- Fast Forward Innovations: Verified investor in Series B
- DCVC Bio: Verified investor in Series B
Key Investors
Peter Thiel
Lead Investor
Verified investor in Series B
Eli Lilly
Investor
Verified investor in Series B
Fast Forward Innovations
Investor
Verified investor in Series B
DCVC Bio
Investor
Verified investor in Series B
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M